



SDI Review Form 1.6

Journal Name:	Ophthalmology Research: An international Journal
Manuscript Number:	2013_OR_5926
Title of the Manuscript:	Effects of micronutrients on serum antioxidant status of glaucoma patients: a randomized, placebo-controlled, double-masked pilot study
Type of the Article	Research Paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments X	1- The dose and period of antioxidant supplementation shall be mentioned much earlier in the manuscript (e.g. abstract) 2- Antioxidant status shall be also performed from the aqueous humor of each patient 3- Data from aqueous humor shall be then compared to serum analysis data 4- Controls: shall specified how the stratification of untreated patients has been performed (intraocular pressure of the controls can be lower than treated patients and this could have biased the interpretation of the data) Please check and provide comparative information 5- Ocuville® Glaukom : please describe this micronutrients complex in the introduction 6- Table 1: "Subjects" shall be replaced by "patients" – Also, please clarify whether these "subjects" are glaucoma patients treated or untreated with the Ocuville® Glaukom. If they are treated patients, please explain why IP < 20 mmHg was a criterium of inclusion: Indeed, one shall expect inclusion of IP > 20 mmHg... In other words, you should perform experiments with untreated and treated groups of glaucoma patients with IP> 20 mmHg and see how the Ocuville® Glaukom works in this context...In your experimental/clinical conditions, the patients may have a low basal	



SDI Review Form 1.6

	antioxidative status that may hamper significant positive effects of Ocuville® Glaucoma... 7- The study is limited by the number of patients... 8- Level of anti-inflammatory markers (enzymes, DNA repair markers) shall have been examined 9- Examination of the eye shall have been performed at different time points in order to see for improved clinical outcome in treated patients (and not only safety concerns based on "unchanged anomalies". 10- I would like to see HPLC data included in the paper. A simple table is insufficient. 11- In the introduction, you should briefly write about actual treatments including Avastin (Anti- angiogenesis drug) 12- Please include in references the following important publications that summarized well the physiopathology and some genetic aspects of Glaucoma: Menea F, Braghini CA, Vasconcellos JP, Menea B, Costa VP, Figueiredo ES, Melo MB. Keeping an eye on myocilin: a complex molecule associated with primary open-angle glaucoma susceptibility. <i>Molecules</i>. 2011 Jun 27;16(7):5402-21.	
--	---	--



SDI Review Form 1.6

<u>Minor</u> REVISION comments		
<u>Optional/General</u> comments		

Reviewer Details:

Name:	Farid Mena
Department, University & Country	Fluorotronics, Inc & Co., USA